| Milo C Engoren, MD | |
|
1500 E Medical Center Dr, Ann Arbor, MI 48109-5000 | |
| (734) 936-4000 | |
| Not Available |
| Full Name | Milo C Engoren |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 42 Years |
| Location | 1500 E Medical Center Dr, Ann Arbor, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306845144 | NPI | - | NPPES |
| 0687243 | Medicaid | OH |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Michigan Health System | Ann arbor, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regents Of The University Of Michigan | 3779496856 | 2953 |
News Archive
A new study suggests that while medication adherence is a critical element in reducing the impact of illness, employers should view it as just one of multiple components that are needed in strategic employee disease-management initiatives.
Researchers have conducted a study suggesting that the B.1.617 lineage of SARS-CoV-2 that emerged in India has evolved a unique strategy.
Patients discontinuing statin medication following an acute myocardial infarction (AMI) increase their risk of dying over the next year, say researchers at McGill University and the McGill University Health Centre (MUHC). Their study was published in a recent issue of the European Heart Journal.
Vigilant Biosciences, Inc., developer of the "rinse and spit" test for assessing early risk of oral cancer, today announced the successful completion of a $2.0 million, oversubscribed Series A financing. The company received $2.3 million in total proceeds, including a $300,000 loan from the Florida Institute for the Commercialization of Public Research Seed Capital Acceleration Program.
› Verified 3 days ago
| Entity Name | Regents Of The University Of Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205868353 PECOS PAC ID: 3779496856 Enrollment ID: O20031106000325 |
News Archive
A new study suggests that while medication adherence is a critical element in reducing the impact of illness, employers should view it as just one of multiple components that are needed in strategic employee disease-management initiatives.
Researchers have conducted a study suggesting that the B.1.617 lineage of SARS-CoV-2 that emerged in India has evolved a unique strategy.
Patients discontinuing statin medication following an acute myocardial infarction (AMI) increase their risk of dying over the next year, say researchers at McGill University and the McGill University Health Centre (MUHC). Their study was published in a recent issue of the European Heart Journal.
Vigilant Biosciences, Inc., developer of the "rinse and spit" test for assessing early risk of oral cancer, today announced the successful completion of a $2.0 million, oversubscribed Series A financing. The company received $2.3 million in total proceeds, including a $300,000 loan from the Florida Institute for the Commercialization of Public Research Seed Capital Acceleration Program.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Milo C Engoren, MD 3621 S State St, Ann Arbor, MI 48108-1633 Ph: (734) 647-5299 | Milo C Engoren, MD 1500 E Medical Center Dr, Ann Arbor, MI 48109-5000 Ph: (734) 936-4000 |
News Archive
A new study suggests that while medication adherence is a critical element in reducing the impact of illness, employers should view it as just one of multiple components that are needed in strategic employee disease-management initiatives.
Researchers have conducted a study suggesting that the B.1.617 lineage of SARS-CoV-2 that emerged in India has evolved a unique strategy.
Patients discontinuing statin medication following an acute myocardial infarction (AMI) increase their risk of dying over the next year, say researchers at McGill University and the McGill University Health Centre (MUHC). Their study was published in a recent issue of the European Heart Journal.
Vigilant Biosciences, Inc., developer of the "rinse and spit" test for assessing early risk of oral cancer, today announced the successful completion of a $2.0 million, oversubscribed Series A financing. The company received $2.3 million in total proceeds, including a $300,000 loan from the Florida Institute for the Commercialization of Public Research Seed Capital Acceleration Program.
› Verified 3 days ago
Paul Derek Fernandes, BM Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1500 East Medical Center Dr, 1h247 University Hospital, Ann Arbor, MI 48109 Phone: 734-936-4280 | |
Thomas F Curran, Anesthesiology Medicare: Medicare Enrolled Practice Location: 2215 Fuller Rd, Ann Arbor, MI 48105 Phone: 734-845-5342 | |
Meghan Horn, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Drive, 1h247 University Hospital, Ann Arbor, MI 48109 Phone: 734-936-4280 | |
Youssef Daklallah, Anesthesiology Medicare: Medicare Enrolled Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 313-525-1834 | |
Austin Michael Foote, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4280 | |
Andrew James Baldock, BM Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1500 East Medical Center Dr, 1h247 University Hospital, Ann Arbor, MI 48109 Phone: 734-936-4280 | |
Monn Y Lee, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1500 East Medical Center Dr, 1h247 University Hospital, Ann Arbor, MI 48109 Phone: 734-936-4280 |